NYSE Shariah screener · October 2026
Is Becton, Dickinson and Company (BDX) Halal?
Becton, Dickinson and Company · NYSE: BDX · Healthcare
The short answer
No - Becton, Dickinson and Company (BDX) fails this Shariah stock screen at the interest-bearing debt gate. Per its Q3 FY2026 10-Q (quarter ended June 30, 2026), interest-bearing debt was $16,808M (current debt obligations $3,297M plus long-term debt $13,511M), which is about 34.65% of its ~$48.5B market cap ($178.07 close on October 1, 2026; 272,386,800 shares outstanding), above the ~33% ceiling. The business gate passes - BD is pure medical technology across four segments (Medical Essentials, Connected Care, BioPharma Systems, Interventional) with no haram segments, following the February 9, 2026 spinoff of its Life Sciences business into Waters Corporation - and the non-compliant income gate passes, with interest income of $16M at about 0.11% of revenue. Third parties differ: Zoya flags BDX as not Shariah-compliant, Musaffa classifies it as halal (October 2026), and ShariaPortfolio rates it Shariah Compliant on 4 of 5 standards.
Gate 1 — Business activity: PASS
Becton, Dickinson and Company (NYSE: BDX), headquartered in Franklin Lakes, New Jersey, is a global medical technology company that develops, manufactures and sells medical supplies, devices and diagnostic products to healthcare institutions, clinical laboratories, life science researchers and physicians. On February 9, 2026, the company completed the spinoff of its former Biosciences and Diagnostic Solutions business (the old BD Life Sciences segment) and its combination with Waters Corporation in a Reverse Morris Trust transaction; that business is now presented as discontinued operations. The four remaining reportable segments are BD Medical Essentials (Medication Delivery Solutions, Specimen Management), BD Connected Care (Medication Management Solutions, Advanced Patient Monitoring), BD BioPharma Systems (Pharmaceutical Systems) and BD Interventional (Urology and Critical Care, Peripheral Intervention, Surgery). Haram flags: none - every segment sells medical devices, diagnostics and pharmaceutical systems; no alcohol, tobacco, gambling, conventional financial services, adult entertainment or pork products appear in the filings. Gate 1 passes. Facts only.
Gate 2 — Debt and cash: FAIL
Per BD's Q3 FY2026 10-Q (quarter ended June 30, 2026, filed August 6, 2026), interest-bearing debt was $16,808M - current debt obligations $3,297M plus long-term debt $13,511M. Against a market cap of about $48.5B ($178.07 close on October 1, 2026; 272,386,800 shares outstanding per the 10-Q cover), debt divided by market cap is about 34.65%, above the ~33% ceiling. Cash and equivalents of $708M are about 1.46% of market cap. Gate 2 fails. Facts only.
Gate 3 — Non-compliant income: PASS
BD's Q3 FY2026 10-Q discloses interest income of $16M as a separate line against total revenues of $14,183M for the nine months ended June 30, 2026 - about 0.11% of revenue, far below the 5% non-compliant income ceiling. The FY2025 10-K shows interest income of $38M against revenue of $21,839M (about 0.17%). The screen fails at Gate 2 (debt ratio), not on non-compliant income. Gate 3 passes. Facts only.
Key figures used
- Business: global medical technology company, Franklin Lakes, New Jersey; four post-spinoff segments - BD Medical Essentials (Medication Delivery Solutions, Specimen Management), BD Connected Care (Medication Management Solutions, Advanced Patient Monitoring), BD BioPharma Systems (Pharmaceutical Systems), BD Interventional (Urology and Critical Care, Peripheral Intervention, Surgery)
- Life Sciences separation: on February 9, 2026 BD spun off its former Biosciences and Diagnostic Solutions business (old Life Sciences segment), which combined with Waters Corporation in a Reverse Morris Trust; presented as discontinued operations
- Haram flags: none - all segments are medical devices, diagnostics and pharmaceutical systems; no alcohol, tobacco, gambling, conventional finance, adult entertainment or pork in the filings
- Debt: $16,808M (current debt obligations $3,297M + long-term debt $13,511M, Q3 FY2026 10-Q) - debt divided by market cap about 34.65% of ~$48.5B, above the ~33% ceiling
- Cash: $708M cash and equivalents - about 1.46% of market cap
- Interest income: $16M vs revenue $14,183M (nine months ended June 30, 2026, 10-Q) - about 0.11% of revenue, under the 5% ceiling; FY2025 10-K: $38M vs $21,839M - 0.17%
- Zoya: not Shariah-compliant (public page, checked Oct 2026, page date field blank); Musaffa: halal (Oct 2026, AAOIFI); ShariaPortfolio: Shariah Compliant, passes 4/5 standards
- Result: FAIL at Gate 2 (interest-bearing debt ratio) - business and non-compliant income gates pass
Frequently asked questions
What does Becton Dickinson do?
Becton, Dickinson and Company (NYSE: BDX), headquartered in Franklin Lakes, New Jersey, is a global medical technology company that develops, manufactures and sells medical supplies, devices and diagnostic products to healthcare institutions, clinical laboratories and researchers. Following the February 9, 2026 spinoff of its former Biosciences and Diagnostic Solutions business (the old Life Sciences segment), which combined with Waters Corporation in a Reverse Morris Trust, BD operates four reportable segments: BD Medical Essentials (Medication Delivery Solutions, Specimen Management), BD Connected Care (Medication Management Solutions, Advanced Patient Monitoring), BD BioPharma Systems (Pharmaceutical Systems) and BD Interventional (Urology and Critical Care, Peripheral Intervention, Surgery). The spun-off business is presented as discontinued operations.
Why does Becton Dickinson fail this Shariah stock screen?
Becton Dickinson fails this screen at the second gate - the interest-bearing debt gate - even though its business activities and non-compliant income ratios pass. Per BD's Q3 FY2026 10-Q (quarter ended June 30, 2026), interest-bearing debt was $16,808M (current debt obligations $3,297M plus long-term debt $13,511M). Against a market cap of about $48.5B ($178.07 close on October 1, 2026; 272,386,800 shares outstanding per the 10-Q cover), debt divided by market cap is about 34.65% - above the ~33% ceiling. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.
What is Becton Dickinson's interest-bearing debt ratio?
Per BD's Q3 FY2026 10-Q (quarter ended June 30, 2026, filed August 6, 2026), interest-bearing debt was $16,808M - current debt obligations of $3,297M plus long-term debt of $13,511M. Against a market cap of about $48.5B ($178.07 close on October 1, 2026; 272,386,800 shares outstanding per the 10-Q cover), debt divided by market cap is about 34.65% - above the ~33% ceiling, so this gate fails. Cash and equivalents of $708M are about 1.46% of market cap.
What is Becton Dickinson's non-compliant income ratio?
BD's Q3 FY2026 10-Q discloses interest income as a separate line: $16M against total revenues of $14,183M for the nine months ended June 30, 2026 - about 0.11% of revenue, far below the 5% non-compliant income ceiling. The FY2025 10-K likewise shows interest income of $38M against revenue of $21,839M (about 0.17%). The financial gate that fails is the debt ratio, not the non-compliant income ratio.
Do Zoya, Musaffa, or ShariaPortfolio cover Becton Dickinson?
Zoya covers BDX and flags it as not Shariah-compliant on its public stock page (checked October 2, 2026; the page's own date field renders blank). Musaffa covers BDX and classifies it as halal as of October 2026 under its AAOIFI methodology, and ShariaPortfolio's screener page states Becton Dickinson and Co is Shariah Compliant and passes 4 of 5 of its standards. The third-party positions genuinely differ; this page applies the screen directly from BD's own filings, where the debt ratio computed against the current market cap exceeds the 33% ceiling.
Sources
- BD - Q3 FY2026 10-Q (filed 08/06/2026; quarter ended June 30, 2026): cover (272,386,800 shares outstanding), balance sheet (debt $16,808M; cash $708M), income statement (revenue $14,183M; interest income $16M, nine months), Notes 1-2 (February 9, 2026 Life Sciences spinoff and Waters combination; four remaining segments)
- BD - FY2025 10-K (fiscal year ended Sept 30, 2025): segment reorganization notes (Medical Essentials, Connected Care, BioPharma Systems, Interventional, Life Sciences - Life Sciences to be eliminated post-combination), revenue $21,839M, interest income $38M
- Finnhub - BDX live quote (current price $178.07; market cap ~$49.3B, October 2026)
- Tradestie - BDX analysis updated Oct 1, 2026 ($178.07, -0.93/-0.52%)
- Zoya - Becton Dickinson (BDX) stock page (flags not Shariah-compliant; cites FY2025 10-K revenue $21,839M and interest income $38M)
- Musaffa - Becton Dickinson and Co (BDX) stock page (classified halal, as of October 2026)
- ShariaPortfolio - BDX screener page (Shariah Compliant, passes 4/5 standards)
Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).